These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 35160082)
21. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Braun J; Baraliakos X; Listing J; Sieper J Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578 [TBL] [Abstract][Full Text] [Related]
22. Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis. Kim MJ; Lee EE; Lee EY; Song YW; Yu HG; Choi Y; Lee EB Clin Rheumatol; 2018 Oct; 37(10):2763-2770. PubMed ID: 30076542 [TBL] [Abstract][Full Text] [Related]
23. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis. Nell-Duxneuner V; Schroeder Y; Reichardt B; Bucsics A Int J Clin Pharmacol Ther; 2012 Dec; 50(12):867-72. PubMed ID: 23036238 [TBL] [Abstract][Full Text] [Related]
24. Characteristics Associated with the Occurrence and Development of Acute Anterior Uveitis, Inflammatory Bowel Disease, and Psoriasis in Patients with Ankylosing Spondylitis: Data from the Chinese Ankylosing Spondylitis Prospective Imaging Cohort. Man S; Ji X; Hu L; Wang Y; Ma Y; Wang L; Zhu J; Huang F Rheumatol Ther; 2021 Mar; 8(1):555-571. PubMed ID: 33709320 [TBL] [Abstract][Full Text] [Related]
25. [Application of TNF-alpha inhibitors in treatment of uveitis associated with ankylosing spondylitis]. Razumova IY; Godzenko AA Vestn Oftalmol; 2018; 134(5. Vyp. 2):257-262. PubMed ID: 30499526 [TBL] [Abstract][Full Text] [Related]
26. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice. Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480 [TBL] [Abstract][Full Text] [Related]
27. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600 [TBL] [Abstract][Full Text] [Related]
29. Association of T-Bet, GATA-3, RORC, and FOXP3 Copy Number Variations With Acute Anterior Uveitis With or Without Ankylosing Spondylitis in Chinese Han. Bai L; Liu Y; Hou S; Liao D; Kijlstra A; Yang P Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1847-52. PubMed ID: 27082299 [TBL] [Abstract][Full Text] [Related]
30. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. Rotar Ž; Tomšič M; Praprotnik S; Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406 [TBL] [Abstract][Full Text] [Related]
31. Role of Tumor Necrosis Factor-α Inhibitors in the Treatment and Occurrence of Acne: A Systematic Review. Sandoval AGW; Vaughn LT; Huang JT; Barbieri JS JAMA Dermatol; 2023 May; 159(5):504-509. PubMed ID: 36930143 [TBL] [Abstract][Full Text] [Related]
32. The role of Vitamin D in immuno-inflammatory responses in Ankylosing Spondylitis patients with and without Acute Anterior Uveitis. Mitulescu TC; Stavaru C; Voinea LM; Banica LM; Matache C; Predeteanu D J Med Life; 2016; 9(1):26-33. PubMed ID: 27713770 [No Abstract] [Full Text] [Related]
33. FoxO1 gene confers genetic predisposition to acute anterior uveitis with ankylosing spondylitis. Yu H; Liu Y; Zhang L; Wu L; Zheng M; Cheng L; Luo L; Kijlstra A; Yang P Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):7970-4. PubMed ID: 25414190 [TBL] [Abstract][Full Text] [Related]
34. Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry. Kim HA; Lee SK; Oh S; Park EH; Park YB; Shin K Front Med (Lausanne); 2021; 8():689609. PubMed ID: 34211991 [TBL] [Abstract][Full Text] [Related]
35. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543 [TBL] [Abstract][Full Text] [Related]
36. Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review. van der Horst-Bruinsma IE; Robinson PC; Favalli EG; Verbraak FD; Kim M; Kumke T; Bauer L; Hoepken B; Deodhar A Rheumatol Ther; 2022 Dec; 9(6):1481-1497. PubMed ID: 36178585 [TBL] [Abstract][Full Text] [Related]
37. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants. Eworuke E; Panucci G; Goulding M; Neuner R; Toh S Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):296-304. PubMed ID: 30430682 [TBL] [Abstract][Full Text] [Related]
38. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401 [TBL] [Abstract][Full Text] [Related]
39. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Bonafede M; Fox KM; Watson C; Princic N; Gandra SR Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712 [TBL] [Abstract][Full Text] [Related]
40. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Kakkassery V; Mergler S; Pleyer U Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]